Advanced Solid Tumors
832
200
244
330
Key Insights
Highlights
Success Rate
76% trial completion
Published Results
108 trials with published results (13%)
Research Maturity
330 completed trials (40% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
12.7%
106 terminated out of 832 trials
75.7%
-10.9% vs benchmark
0%
3 trials in Phase 3/4
33%
108 of 330 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 330 completed trials
Clinical Trials (832)
A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors
A Study of DXC018 in Patients With Advanced Solid Tumors
A Phase 1 Study to Investigate FP008 in Subjects With Advanced Solid Tumors
Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors
A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors
A Study of AK157D1 for Injection in Advanced Solid Tumors
A Study of PHN-012 in Patients With Advanced Solid Tumors
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects With Advanced Solid Tumors
Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas
Safety and Activity of HF50 in Patients With Advanced Solid Tumors
NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies
A Study of JNJ-87890387 for Advanced Solid Tumors
A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors